About Keratin, type I cuticular Ha3-II
Keratin, type I cuticular Ha3-II (KRT33B) is a protein
from Homo sapiens identified by UniProt accession
Q14525, 404 residues long.
MolForge cross-references it against 0 known binders and
26 disease associations.
Target properties
| Protein name | Keratin, type I cuticular Ha3-II |
| UniProt accession | Q14525 |
| Gene | KRT33B |
| Organism | Homo sapiens |
| Length | 404 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (26)
Diseases linked to this target (Open Targets).
- glioblastoma multiforme · score 0.19
- head and neck squamous cell carcinoma · score 0.18
- esophageal cancer · score 0.14
- low grade glioma · score 0.11
- cryptorchidism · score 0.04
- Testicular regression syndrome · score 0.04
- isolated congenital hypogonadotropic hypogonadism · score 0.04
- renal hypodysplasia/aplasia 3 · score 0.04
- 46,XY complete gonadal dysgenesis · score 0.04
- 46,XX ovotesticular disorder of sex development · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14525-F1 | alphafold | PREDICTED | 79.11 | — |
Amino-acid sequence (404 residues)
MPYNFCLPSL SCRTSCSSRP CVPPSCHGYT LPGACNIPAN VSNCNWFCEG SFNGSEKETM QFLNDRLASY LEKVRQLERD NAELENLIRE RSQQQEPLLC PSYQSYFKTI EELQQKILCS KSENARLVVQ IDNAKLAADD FRTKYQTEQS LRQLVESDIN SLRRILDELT LCRSDLEAQM ESLKEELLSL KQNHEQEVNT LRCQLGDRLN VEVDAAPAVD LNQVLNETRN QYEALVETNR REVEQWFATQ TEELNKQVVS SSEQLQSYQA EIIELRRTVN ALEIELQAQH NLRYSLENTL TESEARYSSQ LSQVQSLITN VESQLAEIRS DLERQNQEYQ VLLDVRARLE CEINTYRSLL ESEDCKLPSN PCATTNACEK PIGSCVTNPC GPRSRCGPCN TFGY
Explore Keratin, type I cuticular Ha3-II with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets